The cardiotoxicity of macrolides: A systematic review

Pharmazie

Volumn 65, Issue 9, 2010, Pages 631-640

  Guo, Daihong ^a   Cai, Yun ^a   Chai, Dong ^a   Liang, Beibei ^a   Bai, Nan ^a   Wang, Rui ^a  

^a CHINESE PLA GENERAL HOSPITAL   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ASTEMIZOLE; AZITHROMYCIN; CARBIMAZOLE; CISAPRIDE; CLARITHROMYCIN; CYTOCHROME P450 3A; DESLORATADINE; DIRITHROMYCIN; DISOPYRAMIDE; ERYTHROMYCIN; FEXOFENADINE; KETOCONAZOLE; LEVOCABASTINE; LORATADINE; MACROLIDE; MEQUITAZINE; MOSAPRIDE CITRATE; PIMOZIDE; PLACEBO; QUINIDINE; ROXITHROMYCIN; SOTALOL; SPIRAMYCIN; TELITHROMYCIN; TERFENADINE; VERAPAMIL;

BRONCHITIS; CARDIOTOXICITY; CARDIOVASCULAR RISK; CLINICAL PRACTICE; CLINICAL TRIAL; COMMUNITY ACQUIRED PNEUMONIA; CONTROLLED CLINICAL TRIAL; DIPHTHERIA; DRUG SAFETY; DRUG TOLERABILITY; ELECTROCARDIOGRAPHY; ERYTHEMA; HEPATITIS C; HUMAN; INSULIN DEPENDENT DIABETES MELLITUS; INTERSTITIAL PNEUMONIA; LOBAR PNEUMONIA; MAXIMUM PLASMA CONCENTRATION; MORNING DOSAGE; PATIENT MONITORING; PNEUMONIA; QT INTERVAL; QT PROLONGATION; RANDOMIZED CONTROLLED TRIAL; RESPIRATORY DISTRESS; RESPIRATORY TRACT INFECTION; REVIEW; STAPHYLOCOCCUS INFECTION; SYSTEMATIC REVIEW; SYSTEMIC LUPUS ERYTHEMATOSUS; TORSADE DES POINTES; TOXOPLASMOSIS;

ANTI-BACTERIAL AGENTS; DRUG INTERACTIONS; HEART DISEASES; HUMANS; MACROLIDES;

EID: 77957987217     PISSN: 00317144     EISSN: None     Source Type: Journal    
DOI: 10.1691/ph.2010.0644     Document Type: Review

References (55)

1. Bachmann K, Sullivan TJ, Reese JH, Jauregui L, Miller K, Scott M, Stotka J, Harris J (1997) A study of the interaction between dirithromycin and astemizole in healthy adults. Am J Ther 4: 73-79.
2. Banfield C, Hunt T, Reyderman L, Statkevich P, Padhi D, Affrime M (2002) Lack of clinically relevant interaction between desloratadine and erythromycin. Clin Pharmacokinet 41 (Suppl 1): 29-35.
3. Benoit A, Bodiou C, Villain E, Bavoux F, Checoury A, Badoual J (1991) QT prolongation and circulatory arrest after an injection of erythromycin in a newborn infant. Arch Fr Pediatr 48: 39-41.
4. Brandriss MW, Richardson WS, Barold SS (1994) Erythromycin-induced QT prolongation and polymorphic ventricular tachycardia (torsades de pointes): case report and review. Clin Infect Dis 18: 995-998.
5. Brixius B, Lindinger A, Baghai A, Limbach HG, Hoffmann W(1999) Ventricular tachycardia after erythromycin administration in a newborn with congenital AV-block. Klin Padiatr 211: 465-468.
6. Camilleri JF, Deharo JC, Panagides D, Broin P, Mesana T, Blin D, Mouly-Bandini A, Dubouloz C, Goudard A, Monties JR (1989) Jet intravenous injection of erythromycin lactobionate. A possible cause of the occurrence of crisis in torsade de pointe. Ann Cardiol Angeiol (Paris) 38: 657-659.
7. Carr RA, Edmonds A, Shi H, Locke CS, Gustavson LE, Craft JC, Harris SI, Palmer R (1998) Steady-state pharmacokinetics and electrocardiographic pharmacodynamics of clarithromycin and loratadine after individual or concomitant administration. Antimicrob Agents Chemother 42: 1176-1180.
8. Chennareddy SB, Siddique M, Karim MY, Kudesia V (1996) Erythromycin-induced polymorphous ventricular tachycardia with normal QT interval. Am Heart J 132: 691-694.
9. Choudhury L, Grais IM, Passman RS (1999) Torsades de pointes due to drug interaction between disopyramide and clarithromycin. Heart Dis 1: 206-207.
10. Demolis JL, Strabach S, Vacheron F, Funck-Brentano C (2005) Assessment of the effect of a single oral dose of telithromycin on sotalol-induced qt interval prolongation in healthywomen. Br J Clin Pharmacol 60: 120-127.
11. Demolis JL, Vacheron F, Cardus S, Funck-Brentano C (2003) Effect of single and repeated oral doses of telithromycin on cardiac QT interval in healthy subjects. Clin Pharmacol Ther 73: 242-252.
12. Desta Z, Kerbusch T, Flockhart DA (1999) Effect of clarithromycin on the pharmacokinetics and pharmacodynamics of pimozide in healthy poor and extensive metabolizers of cytochrome P450 2D6 (CYP2D6). Clin Pharmacol Ther 65: 10-20.
13. Germanakis I, Galanakis E, Parthenakis F, Vardas PE, Kalmanti M (2006) Clarithromycin treatment and QT prolongation in childhood. Acta Paediatr 95: 1694-1696.
14. Goldschmidt N, Azaz-Livshits T, Gotsman Nir-Paz, R Ben-Yehuda, A, Muszkat M (2001) Compound cardiac toxicity of oral erythromycin and verapamil. Ann Pharmacother 35: 1396-1399.
15. Gupta, S Banfield, C Kantesaria, B Marino, M Clement, R Affrime, M, Batra V (2001) Pharmacokinetic and safety profile of desloratadine and fexofenadine when coadministered with azithromycin: a randomized, placebo-controlled, parallel-group study. Clin Ther 23: 451-466.
16. Haefeli WE, Schoenenberger, RA Weiss, P, Ritz R (1992) Possible risk for cardiac arrhythmia related to intravenous erythromycin. Intensive Care Med 18: 469-473.
17. Hayashi Y, Ikeda U, Hashimoto T, Watanabe T, Mitsuhashi T, Shimada K (1999) Torsades de pointes ventricular tachycardia induced by clarithromycin and disopyramide in the presence of hypokalemia. Pacing Clin Electrophysiol 22: 672-674.
18. Hensey C, Keane D (2008) Clarithromycin induced torsade de pointes. Ir J Med Sci 177: 67-68.
19. Honig PK, Woosley RL, Zamani K, Conner DP, Cantilena LR Jr. (1992) Changes in the pharmacokinetics and electrocardiographic pharmacodynamics of terfenadine with concomitant administration of erythromycin. Clin Pharmacol Ther 52: 231-238.
20. Hsieh MH, Chen SA, Chiang CE, Tai CT, Lee SH, Wen ZC, Chang MS (1996) Drug-induced torsades de pointes in one patient with congenital long QT syndrome. Int J Cardiol 54: 85-88.
21. Huang BH, Wu CH, Hsia CP, Yin Chen C (2007) Azithromycin-induced torsade de pointes. Pacing Clin Electrophysiol 30: 1579-1582.
22. Iannini PB (2002) Cardiotoxicity of macrolides, ketolides and fluoroquinolones that prolong the QTc interval. Expert Opin Drug Saf 1: 121-128.
23. Iida H, Morita T, Suzuki E, Iwasawa K, Toyo-oka T, Nakajima T (1999) Hypoglycemia induced by interaction between clarithromycin and disopyramide. Jpn Heart J 40: 91-96.
24. Justo D, Mardi T, Zeltser D (2004) Roxithromycin-induced torsades de pointes. Eur J Intern Med 15: 326-327.
25. Kamochi H, Nii T, Eguchi K, Mori T, Yamamoto A, Shimoda K, Ibaraki K (1999) Clarithromycin associated with torsades de pointes. Jpn Circ J 63: 421-422.
26. Katoh T, Saitoh H, Ohno N, Tateno M, Nakamura T, Dendo I, Kobayashi S, Nagasawa K (2003) Drug interaction between mosapride and erythromycin without electrocardiographic changes. Jpn Heart J 44: 225-234.
27. Kdesh A, McPherson CA, Yaylali Y, Yasick D, Bradley K, Manthous CA (1999) Effect of erythromycin on myocardial repolarization in patients with community-acquired pneumonia. South Med J 92: 1178-1182.
28. Keskin S, Sayali E, Temeloglu E, Gurol T, Ekizoglu I (2005) QT prolongation and ventricular tachycardia due to roxithromycin. Anadolu Kardiyol Derg 5: 319-321.
29. Kezerashvili A, Khattak H, Barsky A, Nazari R, Fisher JD (2007) Azithromycin as a cause of QT-interval prolongation and torsade de pointes in the absence of other known precipitating factors. J Interv Card Electrophysiol 18: 243-246.
30. Kneen R, Pham NG, Solomon T, Tran TM, Nguyen TT, Tran BL, Wain J, Day NP, Tran TH, Parry CM, White NJ (1998) Penicillin vs. erythromycin in the treatment of diphtheria. Clin Infect Dis 27: 845-850.
31. Koh TW (2001) Risk of torsades de pointes from oral erythromycin with concomitant carbimazole (methimazole) administration. Pacing Clin Electrophysiol 24: 1575-1576.
32. Kyrmizakis DE, Chimona TS, Kanoupakis EM, Papadakis CE, Velegrakis GA, Helidonis ES (2002) QT prolongation and torsades de pointes associated with concurrent use of cisapride and erythromycin. Am J Otolaryngol 23: 303-307.
33. Lengyel C, Varkonyi T, Fazekas T (1997) Erythrocyte-induced "torsade de pointes" ventricular tachycardia. Orv Hetil 138: 1003-1006.
34. Lin JC, Quasny HA (1997) QT prolongation and development of torsades de pointes with the concomitant administration of oral erythromycin base and quinidine. Pharmacotherapy 17: 626-630.
35. Malcolm A (2000) Commentary-QT prolongation due to roxithromycin. Postgrad Med J 76: 653-654.
36. Milberg P, Eckardt L, Bruns HJ, Biertz J, Ramtin S, Reinsch N, Fleischer D, Kirchhof P, Fabritz L, Breithardt G, Haverkamp W (2002) Divergent proarrhythmic potential of macrolide antibiotics despite similar QT prolongation: fast phase 3 repolarization prevents early afterdepolarizations and torsade de pointes. J Pharmacol Exp Ther 303: 218-225.
37. Mishra A, Friedman HS, Sinha AK (1999) The effects of erythromycin on the electrocardiogram. Chest 115: 983-986.
38. Oberg K, Fau-Bauman JL, Bauman JL (1995) QT interval prolongation and torsades de pointes due to erythromycin lactobionate. Pharmacotherapy 15: 687-692.
39. Orban Z, MacDonald LL, Peters MA, Guslits B (1995) Erythromycin-induced cardiac toxicity. Am J Cardiol 75: 859-861.
40. Pesco-Koplowitz L, Hassell A, Lee P, Zhou H, Hall N, Wiesinger B, Mechlinski W, Grover M, Hunt T, Smith R, Travers S (1999) Lack of effect of erythromycin and ketoconazole on the pharmacokinetics and pharmacodynamics of steady-state intranasal levocabastine. J Clin Pharmacol 39: 76-85.
41. Piquette RK (1999) Torsade de pointes induced by cisapride/clarithromycin interaction. Ann Pharmacother 33: 22-26.
42. Promphan W, Khongphatthanayothin A, Horchaiprasit K, Benjacholamas V (2003) Roxithromycin induced torsade de pointes in a patient with complex congenital heart disease and complete atrioventricular block. Pacing Clin Electrophysiol 26: 1424-1426.
43. Ray WA, Murrayr KT, Meredith S, Narasimhulu SS, Hall K, Stein CM (2004) Oral erythromycin and the risk of sudden death from cardiac causes. N Engl J Med 351: 1089-1096.
44. Rezkalla MA, Pochop C (1994) Erythromycin induced Torsades de Pointes: case report and review of the literature. S D J Med 47: 161-164.
45. Rubinstein E (2001) Comparative safety of the different macrolides. Int J Antimicrob Agents 18 (Suppl 1): S71-76.
46. Russo V, Puzio G, Siniscalchi N (2006) Azithromycin-induced QT prolongation in elderly patient. Acta Biomed 77: 30-32.
47. Schoenenberger RA, Haefeli WE, Weiss P, Ritz RF (1990) Association of intravenous erythromycin and potentially fatal ventricular tachycardia with Q-T prolongation (torsades de pointes). BMJ 300: 1375-1376.
48. Sekkarie MA (1997) Torsades de pointes in two chronic renal failure patients treated with cisapride and clarithromycin. Am J Kidney Dis 30: 437-439.
49. Shi J, Chapel S, Montay G, Hardy P, Barrett JS, Sica D, Swan SK, Noveck R, Leroy B, Bhargava VO (2005) Effect of ketoconazole on the pharmacokinetics and safety of telithromycin and clarithromycin in older subjects with renal impairment. Int J Clin Pharmacol Ther 43: 123-133.
50. Stramba-Badiale M, Nador F, Porta N, Guffanti S, Frediani M, Colnaghi C, Grancini F, Motta G, Carnelli V, Schwartz PJ (1997) QT interval prolongation and risk of life-threatening arrhythmias during toxoplasmosis prophylaxis with spiramycin in neonates. Am Heart J 133: 108-111.
51. Strle F, Maraspin V (2002) Is azithromycin treatment associated with prolongation of the Q-Tc interval? Wien Klin Wochenschr 114: 396-399.
52. Tilelli JA, Smith KM, Pettignano R (2006) Life-threatening bradyarrhythmia after massive azithromycin overdose. Pharmacotherapy 26: 147-150.
53. van Haarst AD, van 't Klooster GA, van Gerven JM, Schoemaker RC, van Oene JC, Burggraaf J, Coene MC, Cohen AF (1998) The influence of cisapride and clarithromycin on QT intervals in healthy volunteers. Clin Pharmacol Ther 64: 542-546.
54. Verdun F, Mansourati J, Jobic Y, Bouquin V, Munier S, Guillo P, Pages Y, Boschat J, Blanc JJ (1997) Torsades de pointe with spiramycine and metiquazine therapy. Apropos of a case. Arch Mal Coeur Vaiss 90: 103-106.
55. Woywodt A, Grommas U, Buth W, Rafflenbeul W (2000) QT prolongation due to roxithromycin. Postgrad Med J 76: 651-653.